276 related articles for article (PubMed ID: 18938080)
1. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
2. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
3. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
5. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
7. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
Rossi AB; Herlaar E; Braselmann S; Huynh S; Taylor V; Frances R; Issakani SD; Argade A; Singh R; Payan DG; Masuda ES
J Allergy Clin Immunol; 2006 Sep; 118(3):749-55. PubMed ID: 16950297
[TBL] [Abstract][Full Text] [Related]
9. Highly potent aminopyridines as Syk kinase inhibitors.
Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
[TBL] [Abstract][Full Text] [Related]
10. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
[TBL] [Abstract][Full Text] [Related]
13. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Aug; 16(15):7347-57. PubMed ID: 18585046
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.
van Bree SH; Gomez-Pinilla PJ; van de Bovenkamp FS; Di Giovangiulio M; Farro G; Nemethova A; Cailotto C; de Jonge WJ; Lee K; Ramirez-Molina C; Lugo D; Skynner MJ; Boeckxstaens GE; Matteoli G
Gut; 2013 Nov; 62(11):1581-90. PubMed ID: 23242119
[TBL] [Abstract][Full Text] [Related]
15. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
[TBL] [Abstract][Full Text] [Related]
17. A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response.
Ramis I; Otal R; Carreño C; Domènech A; Eichhorn P; Orellana A; Maldonado M; De Alba J; Prats N; Fernández JC; Vidal B; Miralpeix M
Pharmacol Res; 2015 Sep; 99():116-24. PubMed ID: 26051661
[TBL] [Abstract][Full Text] [Related]
18. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
[TBL] [Abstract][Full Text] [Related]
19. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives.
Hisamichi H; Naito R; Toyoshima A; Kawano N; Ichikawa A; Orita A; Orita M; Hamada N; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2005 Aug; 13(16):4936-51. PubMed ID: 15990316
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
Blake JF; Gaudino JJ; De Meese J; Mohr P; Chicarelli M; Tian H; Garrey R; Thomas A; Siedem CS; Welch MB; Kolakowski G; Kaus R; Burkard M; Martinson M; Chen H; Dean B; Dudley DA; Gould SE; Pacheco P; Shahidi-Latham S; Wang W; West K; Yin J; Moffat J; Schwarz JB
Bioorg Med Chem Lett; 2014 Jun; 24(12):2635-9. PubMed ID: 24813737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
